Federal Minister for Health, Peter Dutton today announced new listings to the PBS including two new oral MS medications.
Aubagio was approved by the Therapeutic Goods Administration (TGA) in 2012 and Tecfidera received TGA approval in July 2013. Both have been shown in clinical trials to reduce relapse rates and slow the rate of disability progression in people with relapsing remitting MS.
The Pharmaceutical Benefits Advisory Committee (PBAC) recommended Aubagio and Tecfidera for PBS listing earlier this year. Today the Government announced that it had passed final approval for the drugs which should be available for reimbursement within the next few months.
As people with MS respond differently to treatments and the side-effect profiles of drugs differ, a wider range of treatment choices is a welcome development. This latest development brings the number of disease modifying medications for relapsing remitting MS to a total of nine, with three oral medications, five injectable treatments and one monthly infusion.
MS Research Australia welcomes new treatments that have undergone rigorous clinical testing as a way of giving people living with MS more options in reducing the impact of the disease on their lives.
‘This is an excellent outcome for people with MS around Australia. It provides further affordable treatment options that will enable people with MS and their doctors to find effective therapies suited to their individual circumstances,’ said Dr. Matthew Miles, Chief Executive Officer of MS Research Australia.
MS Research Australia advise that individuals with MS should discuss treatment options with their neurologists and further information can also be obtained through your state MS society:
Further information on MS treatments can be found on the MS Australia website.